A Multicenter Phase 1 Study of γ -secretase inhibitor RO4929097 in Combination with Capecitabine in Refractory Solid Tumors

BACKGROUND: RO4929097 is an oral inhibitor of γ -secretase that results in Notch signaling inhibition. Prior work has demonstrated that Notch signaling inhibition enhances chemotherapy sensitivity of cancer cells. This phase I study was conducted to determine maximum tolerated dose (MTD), toxicities...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Invest New Drugs
Glavni autori: LoConte, Noelle K., Razak, Albiruni R. A., Ivy, Percy, Tevaarwerk, Amye, Leverence, Rachael, Kolesar, Jill, Siu, Lillian, Lubner, Sam J., Mulkerin, Daniel L., Schelman, William R., Deming, Dustin A., Holen, Kyle D., Carmichael, Lakeesha, Eickhoff, Jens, Liu, Glenn
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297251/
https://ncbi.nlm.nih.gov/pubmed/25318436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0166-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items